top of page
Search

July 29, 2020

Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP, 1% (Twice-A-Day) in 30 g and 60 g tubes a generic version of reference listed drug CLEOCIN T® (Clindamycin Phosphate) 1% Topical Gel.. For more updates, please feel free to email us info@solaris-pharma.com

100 views0 comments

Recent Posts

See All

Mar 20, 2023

Solaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.

Aug 13, 2021

Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP

Comments


bottom of page